We are international

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
previous     next      view all

Updated IMF Publication: "Understanding Bisphosphonate Therapy"
If you are a myeloma patient with bone disease (osteoporosis, lytic lesions, or even hypercalcemia), you will want to read our latest updated publication, "Understanding Bisphosphonate Therapy" This booklet is devoted to therapy that is given to patients with myeloma bone involvement. Approximately 80% of myeloma patients develop bone disease. Bisphosphonates help to prevent skeletal complications of myeloma. Treatment with bisphosphonates reduces bone damage and, when the myeloma is well controlled, allows bone healing to occur.

Should Gadolinium be Used as Part of MRI Testing?
The IMF is continuing the weekly web series #AskDrDurie with IMF Chairman Dr. Brian Durie answering patient-submitted questions in new original videos for IMF-TV. Whether you’d like to know more about the status of various clinical trials or IMF projects, or have questions about new drug regimens or side effects, you can ask Dr. Durie directly. Submit your questions to AskDrDurie@myeloma.org or via social media using the hashtag #AskDrDurie. And be sure to check out the right-hand column of each week’s Minute for the latest episode.

Crowdfunding Myeloma Clinical Trials: What Could Go Wrong?
There has been a lot of discussion lately about crowdfunded campaigns for cancer research and other aid. Crowdfunding is the act of raising money from a large number of individuals on the internet for a specific project or venture, and IMF Chairman Dr. Brian Durie weighs in on what those types of campaigns mean for the cancer community in a new blog post. CLICK HERE to read Dr. Durie’s blog.

Updated IMF Publication: "Understanding Dexamethasone and Other Steroids"

This booklet is devoted to an important component of almost all myeloma therapies. The steroid dexamethasone is a synthetic adrenocortical steroid, also known as glucocorticosteroid or corticosteroid. Dexamethasone is one of the most frequently used medications in the treatment of myeloma. It is also known by the brand names Decadron®, Dexasone®, Diodex®, Hexadrol®, and Maxidex®.

Updated IMF Publication: "Understanding MGUS and Smoldering Myeloma"
This new IMF booklet contains information about monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).Neither is an active disease state, but both are precursor states to active myeloma. It is therefore important to understand if, when, and how active myeloma might evolve and what monitoring and/or interventions are appropriate. CLICK HERE to download and read “Understanding MGUS and Smoldering Myeloma.”

IMF's Asian Myeloma Network Will Provide Access to Pomalidomide in Asia
Access to new drugs outside of the US is frequently delayed by several years following FDA approval in the US, and this delay has a significant negative impact for international myeloma patients. However, a big step has just been taken thanks to the IMF's Asian Myeloma Network (AMN), which has successfully negotiated with the Celgene Corporation to establish an individual or “named” patient access program for pomalidomide in Asia. "This is a model through which patients can gain early access to new drugs which can be literally lifesaving!" IMF Chairman Dr. Brian Durie writes in a new blog.

Updated IMF Multiple Myeloma Patient Handbook available to Download
One of the most daunting aspects of being diagnosed with myeloma is learning about – and understanding – an unfamiliar disease that is quite complicated. The updated 2015 edition of the IMF’s Patient Handbook provides an excellent overview of myeloma. Prepared by Dr. Durie, it focuses on what to do when myeloma is first discovered, the tests you really need, initial treatment options, and supportive care and how to get it. The Patient Handbook is meant to furnish you with the tools to understand and better manage your myeloma. Your caregivers, family, and friends may also find the information useful. CLICK HERE to download a copy of the handbook.

New IMWG Guidelines on the Role of MRI in Myeloma
This week, the IMF’s research division, the International Myeloma Working Group (IMWG), published guidelines in the Journal of Clinical Oncology on the use of MRI (magnetic resonance imaging) in myeloma. The IMWG guidelines recommend that all patients with smoldering or asymptomatic myeloma undergo whole-body MRI, or spine and pelvic MRI if whole body MRI is not available. This recommendation is in sync with the IMWG’s “New Diagnostic Criteria” for myeloma, published in November in the Lancet Oncology, in which the presence of more than one MRI lesion is identified as a basis for considering starting full anti-myeloma therapy. The guidelines note that MRI at diagnosis of symptomatic patients (based upon presence of CRAB criteria) provides prognostic information but does not change treatment selection. The IMF’s IMWG is the leader in developing guidelines for the diagnosis, monitoring, and treatment of myeloma. CLICK HERE to read the guidelines. CLICK HERE to watch IMF Chairman Dr. Brian Durie explain the importance of MRI in smoldering myeloma in #AskDrDurie.

In case you missed it, click here for the Best of ASH 2014 replay

Join Dr. Brian G.M. Durie as he discusses the latest news from the American Society of Hematology (ASH) Conference which recently convened in San Francisco on December 6-8th.

The ASH annual meeting is the largest global blood cancer meeting, featuring over 3,000 scientific abstracts, and was attended by more than 20,000 medical professionals.

Where Do New Myeloma Drugs Come From?
This week, IMF Chairman Dr. Brian Durie provides expert insight on the development of drugs for myeloma treatment in his blog. He answers the important questions: “What is the driving force behind new drug development in myeloma?” and “Do we expect new drugs to keep coming?” Dr. Durie writes about the development of myeloma drugs available today and provides insight on where drug development may be headed in the future. READ MORE in his blog.

previous     next      view all